Drug Facts
Composition & Profile
Identifiers & Packaging
HOW SUPPLIED Halcinonide Cream, USP 0.1% contains halcinonide, USP. The white to off-white cream is available as follows: NDC 0378-8056-49 carton containing one 30 g tube NDC 0378-8056-60 carton containing one 60 g tube Storage: Store at 20ºC to 25ºC (68ºF to 77ºF). [See USP Controlled Room Temperature.] Avoid excessive heat (104°F). To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: DPT Laboratories, Ltd. San Antonio, TX 78215 U.S.A. 141101-0819 Revised: 8/2019 DPT:HALCCR:R2; PRINCIPAL DISPLAY PANEL – 0.1% NDC 0378-8056-49 Halcinonide Cream, USP 0.1% FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE. Rx only Net Wt. 30 g Each gram contains 1 mg halcinonide, USP (0.1%) in a cream base consisting of cetyl alcohol, dimethicone 360, glyceryl stearate, isopropyl palmitate, nitrogen, polysorbate 60, propylene glycol, purified water, and titanium dioxide. USUAL DOSAGE: Apply to the affected area 2 to 3 times daily. See package insert. Store at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.] Avoid excessive heat (104ºF). See flap of carton or crimp of tube for Exp. date and Lot number. Keep this and all medication out of the reach of children. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. DPT:8056:49:1C:R3 117586-0819 Mylan.com Halcinonide Cream, USP 0.1% Carton Label
- HOW SUPPLIED Halcinonide Cream, USP 0.1% contains halcinonide, USP. The white to off-white cream is available as follows: NDC 0378-8056-49 carton containing one 30 g tube NDC 0378-8056-60 carton containing one 60 g tube Storage: Store at 20ºC to 25ºC (68ºF to 77ºF). [See USP Controlled Room Temperature.] Avoid excessive heat (104°F). To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: DPT Laboratories, Ltd. San Antonio, TX 78215 U.S.A. 141101-0819 Revised: 8/2019 DPT:HALCCR:R2
- PRINCIPAL DISPLAY PANEL – 0.1% NDC 0378-8056-49 Halcinonide Cream, USP 0.1% FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE. Rx only Net Wt. 30 g Each gram contains 1 mg halcinonide, USP (0.1%) in a cream base consisting of cetyl alcohol, dimethicone 360, glyceryl stearate, isopropyl palmitate, nitrogen, polysorbate 60, propylene glycol, purified water, and titanium dioxide. USUAL DOSAGE: Apply to the affected area 2 to 3 times daily. See package insert. Store at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.] Avoid excessive heat (104ºF). See flap of carton or crimp of tube for Exp. date and Lot number. Keep this and all medication out of the reach of children. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. DPT:8056:49:1C:R3 117586-0819 Mylan.com Halcinonide Cream, USP 0.1% Carton Label
Overview
The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The steroids in this class include halcinonide. Halcinonide is designated chemically as 21-Chloro-9-fluoro-11β,16α,17-trihydroxypregn-4-ene-3,20-dione cyclic 16,17-acetal with acetone. Graphic formula: C 24 H 32 C1FO 5 MW 454.96 Each gram of 0.1% halcinonide cream, USP contains 1 mg halcinonide, USP in a specially formulated cream base consisting of cetyl alcohol, dimethicone 360, glyceryl stearate, isopropyl palmitate, nitrogen, polysorbate 60, propylene glycol, purified water, and titanium dioxide. Halcinonide Structural Formula
Indications & Usage
Halcinonide cream, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage & Administration
Apply the 0.1% halcinonide cream to the affected area two to three times daily. Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a small amount of cream into the lesion until it disappears. Reapply the preparation leaving a thin coating on the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply halcinonide cream under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional cream should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Warnings & Precautions
No warnings available yet.
Contraindications
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Adverse Reactions
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.